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Ischemia-reperfusion injury in the heart is characterized by marked
infiltration of neutrophils in the myocardial interstitial space. Studies
in human, canine, and murine models have revealed oncostatin M
(OSM) expression in infiltrating leukocytes. In an effort to assess
possible roles of OSM in the myocardium, we used cardiac fibroblasts
(mCFs) isolated from adult mouse heart to determine whether recom-
binant murine OSM regulates the synthesis and release of MIP2/
CXCL2, KC/CXCL1, and LIX/CXCL5, which are three potent neu-
trophil chemoattractants in the mouse. Our results demonstrate that
mCFs express OSM receptors and that, within the IL-6 cytokine
family, OSM uniquely induces significant release of KC and LIX in
mCFs. In addition, although OSM activates the JAK-signal transduc-
ers and activators of transcription and MAPK pathways, we demon-
strate that the OSM-mediated CXC chemokine release in mCFs is also
dependent on the activation of the phosphatidylinositol 3-kinase
pathway.
inflammation; cytokine; neutrophil
ONCOSTATIN M (OSM) belongs to the IL-6 family of cytokines,
which includes IL-6, leukemia-inhibitory factor (LIF), IL-11,
cardiotrophin-1 (CT-1), and ciliary neurotrophic factor (37).
The IL-6 family of cytokine receptors requires dimerization
with glycoprotein 130 (gp130), a glycoprotein cell surface
receptor, for intracellular signaling. The members of the IL-6
family of cytokines frequently cause overlapping molecular
responses [e.g., signal transducer and activator of transcription
(STAT3) activation], although specific nonredundant functions
for many members of the family have been established (20).
OSM as well as several members of the IL-6 cytokine family
are known to activate fibroblasts and to regulate the synthesis
of matrix metalloproteinases and their inhibitors in these cells
(24, 25, 42). However, the results of studies in the human, rat,
and mouse have supported the notion that OSM is involved
uniquely in the regulation of inflammation (15, 22, 23, 26, 27,
28, 31). OSM is primarily produced in and released by acti-
vated monocytes, T lymphocytes, and neutrophils (4, 16, 32),
and it is found in a variety of inflammatory sites. In the human
lung during acute lung injury, infiltrating neutrophils secrete
OSM (15). OSM levels also are elevated in the sera of patients
with rheumatoid arthritis (28) as well as in patients with
inflamed skin (36) and periodontitis (23). In addition, in vitro
studies have demonstrated that OSM not only regulates the
remodeling function of fibroblasts but also elicits inflammatory
responses in these cells. OSM induces the CC chemokines
eotaxin (26) (an eosinophil chemoattractant) and monocyte
chemoattractant protein 1 (25) in mouse lung and in synovial
fibroblasts, respectively. Moreover, overexpression of OSM in
the mouse lung results in increased recruitment of eosinophils
(26). Altogether, these studies suggest that OSM regulates
inflammatory function in fibroblasts and that fibroblasts may
be implicated in the recruitment of leukocytes upon activation
by OSM.
Members of the IL-6 family of cytokines are also found in
stressed or injured myocardium (3, 13, 17, 29, 40, 43). Previ-
ous studies conducted at our laboratory showed that IL-6 is
induced and synthesized in the myocardial infarction border
zone after reperfusion (17). More recently, Gwechenberger et
al. (18) demonstrated that OSM was present in leukocytes
during a 7-day observation period in a canine model of myo-
cardial reperfusion. Ischemia-reperfusion injury in the heart is
characterized by early extravasation of neutrophils and mono-
cytes into the myocardial interstitial space (7, 9, 11), and
myocardial damage after reperfusion of ischemic tissue is
caused primarily by infiltrating neutrophils. The recruitment of
neutrophils into the extravascular space of various organs is
regulated in part by the  (CXC) chemokine family of inflam-
matory and immunoregulatory cytokines, which include hu-
man IL-8/CXC ligand 8 (IL-8/CXCL8), the growth-related
oncogene isoforms (GRO-, -, and -/CXCL1, CXCL2, and
CXCL3), epithelial neutrophil-activating peptide (ENA-78/
CXCL5), and mouse macrophage inflammatory protein
2/CXCL2 (MIP2/CXCL2), renal keratinocyte-derived chemo-
kine (KC/CXCL1), and LPS-induced chemokine (LIX/
CXCL5) (6, 30). Whether OSM regulates the recruitment of
leukocytes in the ischemic reperfused heart is not known.
Among interstitial cells, masts cells and resident macro-
phages have been suggested to contribute to leukocyte recruit-
ment in extravascular spaces (10, 14). Whether cardiac fibro-
blasts, the most abundant resident interstitial cells in the heart,
contribute to leukocyte recruitment in the reperfused heart is
not known. Although it was previously established that cardiac
fibroblasts can synthesize and release a variety of cytokines in
vitro (8, 44), whether they synthesize the chemokines involved
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in the recruitment of leukocytes at the site of inflammation is
not known and whether OSM can regulate chemokine synthe-
sis in cardiac fibroblasts has not been studied. Therefore, using
mouse cardiac fibroblasts (mCFs) isolated from adult mouse
heart, we sought to determine in the present study whether
recombinant mouse OSM can regulate the synthesis and re-
lease of MIP2/CXCL2, KC/CXCL1, and LIX/CXCL5, which
are three potent neutrophil chemoattractants in the mouse. We
have demonstrated selectivity among the members of the IL-6
family of cytokines to regulate CXC chemokines in mCFs, and
that OSM triggers highly specific chemokine expression in
mCFs. In addition, we have demonstrated that the OSM-
mediated response is dependent on the phosphatidylinositol
3-kinase (PI3-kinase) pathway. We compared the response of
Fig. 1. Flow cytometric analysis of the surface
expression of oncostatin M (OSM) receptor
(OSMR), IL-6 receptor (IL6R), glycoprotein 130
(gp130), as well as RT-PCR analysis of mRNA
expression of IL-6 cytokine family receptors in
adult murine cardiac fibroblasts (mCFs) isolated
from adult mouse heart and NIH 3T3 cells. mCFs
(A–C) and NIH 3T3 cells (D–F) were incubated
with MAbs to mouse OSMR and IL6R, with goat
PAb against mouse gp130, and with the appro-
priate rat or goat IgG isotype controls. The cells
were incubated with FITC- or phycoerythrin
(PE)-labeled secondary antibody and were ana-
lyzed as described in MATERIALS AND METHODS.
Histograms are representative of 3 experiments
for mCFs and of 2 experiments for NIH 3T3 cells.
Rightward shifts of the histograms (receptors)
from filled histograms (IgG control) indicate the
presence of the specific receptor on the cell sur-
faces. G: mRNA expression of cytokine receptors
by RT-PCR in unstimulated mCFs (lanes 1–5),
and NIH 3T3 cells (lanes 6–10). Top bands (ar-
row), GAPDH; bottom bands, gp130, lanes 1 and
6; OSMR, lanes 2 and 7; IL6R, lanes 3 and 8;
leukemia-inhibitory factor (LIF) receptor, lanes 4
and 9; IL-11 receptor, lanes 5 and 10.
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primary mCFs with that of embryonic NIH 3T3 cells to
elucidate the pertinent signaling pathways involved in this
regulation.
MATERIALS AND METHODS
Preparation of cardiac fibroblasts. Mouse cardiac fibroblasts
(mCFs) were isolated and cultured according to the method described
previously by Eghbali (8) and Zeydel et al. (44) with little modifica-
tion. Left and right ventricles and septa obtained from three to five
12-wk-old C57BL/6J mouse hearts were minced and digested in 100
U/ml type 2 collagenase (CLS2; Worthington Biochemical, Lake-
wood, NJ) at 37°C. Supernatants were filtered through a 70-m filter.
Cells passed through the filter were pelleted, washed to remove the
collagenase, and then resuspended in DMEM containing 10% FBS
and antibiotics (100 U/ml penicillin G, 100 g/ml streptomycin sulfate,
and 0.25 g/ml amphotericin B; GIBCO-BRL, Grand Island, NY),
plated on 25- or 75-cm2 flasks, and incubated at 37°C. Adherent cells
were characterized at passage 1 using immunofluorescence micros-
copy and found to be positive for vimentin and smooth muscle -actin
but negative for desmin and CD31 (platelet endothelial cell adhesion
molecule 1, a leukocyte and endothelial cell marker). Fibroblasts up to
passage 4 were used in these studies. NIH 3T3 cells (American Type
Culture Collection, Manassas, VA) were cultured in the same medium
as mCFs. Before (16 h) each experiment, cells were incubated in
DMEM with 2% serum. Cells were washed three times in HBSS
before being treated with cytokines. All experiments were performed
in serum-free DMEM.
Cytokines and inhibitors. Mouse recombinant OSM, LIF, IL-6,
IL-11, CT-1, and TNF-, and neutralization antibody against mouse
OSM were purchased from R&D Systems (San Diego, CA). Endo-
toxin levels were 0.1 ng/g recombinant mouse cytokine as tested
by the manufacturer using the limulus amebocyte lysate method. The
pharmacological inhibitors LY-294002 (a specific inhibitor of the
PI3-kinase pathway), PD-98059 (a pharmacological inhibitor of the
MAPK pathway), and AG 490 (a pharmacological inhibitor of JAK2)
were purchased from Calbiochem (San Diego, CA). MAb against
MIP2, KC, and LIX for capture, as well as biotinylated PAb MIP2,
KC, LIX, and horseradish peroxidase (HRP) and substrate for detec-
tion were obtained from R&D Systems. Primary antibodies against
mouse OSM receptor (OSMR) and IL-6 receptor for fluorescence-
activated cell sorting were obtained from BD Pharmingen (San Jose´,
CA), and anti-mouse gp130 was purchased from R&D Systems.
FITC- and phycoerythrin (PE)-conjugated secondary antibodies were
obtained from Sigma (St. Louis, MO).
ELISA. Fibroblasts were seeded at an initial concentration of 5,000
cells/cm2 in 12- or 24-well plates. After cytokine stimulation, super-
natants were collected and frozen at 80°C when not used immedi-
ately. ELISA was performed in 96-well plates (Thermo Electron,
Waltham, MA). Plates were coated with anti-mouse KC, LIX, or
MIP2 MAb overnight and then blocked for 1 h with PBS containing
1% BSA. Samples were incubated for 2 h, washed, and biotin-
conjugated secondary antibodies were added for 2 h. Streptavidin-
HRP and substrates were used for color development. Plates were read
and analyzed on a SpectraMax 96-well plate reader running SoftMAX
Pro 3.1 software (Molecular Devices, Sunnyvale, CA). MIP2 and KC
protein standards were obtained from R&D Systems, and LIX was
from PeproTech (Rocky Hill, NJ).
Flow cytometry. Mouse cardiac fibroblasts were detached from
plates using trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA.4Na),
washed in ice-cold PBS buffer, resuspended, incubated with primary
antibody for 20 min, washed and incubated with FITC- or PE-labeled
secondary antibody, and fixed in 1% paraformaldehyde. Analysis was
performed on a FACScan device using CellQuest software (BD
Biosciences, San Diego, CA).
Western blot analysis. Mouse cardiac fibroblasts and NIH 3T3 cells
were lysed in ice-cold SDS lysis buffer containing 100 g/ml PMSF.
Fig. 2. Dose-response relationships of OSM-stimulated release of  (CXC)
chemokine family of inflammatory and immunoregulatory cytokines renal
keratinocyte-derived chemokine (KC), LPS-induced CXC (LIX), and macro-
phage inflammatory protein 2 (MIP2). mCFs were plated in 24-well plates and
treated in serum-free media with increasing doses of OSM for 24 h (A) or
TNF- (B). For blocking studies, mCFs were incubated with 10 g/ml
OSM-neutralizing antibodies before addition of recombinant OSM for 24 h as
described in MATERIALS AND METHODS. Protein amounts of KC, LIX, and MIP2
released in cell culture supernatants were measured by performing specific
sandwich ELISA. Data represent means  SE of 4 independent experiments
performed in triplicate (A, C, and D). Data in B represent 3 experiments. *P 
0.05, **P  0.01, and ***P  0.001 vs. control.
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Lysates were sonicated and then centrifuged at 14,000 g for 10 min.
Lysate supernatant was collected and frozen at 80°C if not used
immediately. Protein concentration was determined using the bicin-
choninic acid protein assay (Pierce Biotechnology, Rockford, IL), and
equal amounts of protein were loaded onto 10% SDS-PAGE gels.
Proteins were then transferred onto PVDF membrane (MSI, Westbor-
ough, MA). Membranes were blocked in PBS containing 5% low-fat
milk powder or horse serum, probed with antibodies to ERK1/2 (BD
Pharmingen), to STAT1 and STAT3 (BD Pharmingen), to Akt1/2
(Santa Cruz Biotechnology, Santa Cruz, CA), and to their phosphor-
ylated states. Blots were incubated with HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology), and bands were visualized
using an ECL Plus detection system (Amersham Pharmacia Biotech,
Piscataway, NJ). Signals from phosphorylated proteins were assessed
first, and then the blots were stripped and subsequently probed with
antibodies against total protein.
RNA isolation and analysis by RNase protection assay. Total RNA
was isolated from mCFs using acid guanidinium thiocyanate-phenol-
chloroform. The quantitation and quality of RNA were assessed on the
basis of A260/A280 UV absorption. The mRNA expression levels of
KC and MIP2 were determined using a RNase protection assay
(RiboQuant; BD Pharmingen) according to the manufacturer’s proto-
col. Phosphorimaging of the gels was performed (Storm 860; Molec-
ular Dynamics, Sunnyvale, CA), and signals were quantified using
ImageQuant software (Molecular Dynamics) and normalized to
housekeeping gene L32.
RT-PCR. mRNA for mouse OSM, IL-6, LIF, and IL-11 receptors,
as well as mRNA for gp130 and GAPDH, were assayed in unstimu-
lated mCFs and NIH 3T3 cells by RT-PCR using specific primers.
LIX mRNA in OSM-treated mCFs was assayed by RT-PCR using
specific primers (see Supplemental Data; http://ajp-cell.physiology.
org/cgi/content/full/00322.2005/DC1/).
Statistical analysis. Data are means  SE. For statistical analysis,
we used one-way ANOVA, followed by Student-Newman-Keuls
posttest. Differences in which P  0.05 were considered significant.
RESULTS
Expression of OSMR on mCFs and CXC chemokine secre-
tion after OSM treatment. Figure 1 shows that mCFs bind
antibodies to the OSMR and its associated gp130 coreceptor
(Fig. 1, A and B). The flow cytometric pattern for mCFs was
similar to that observed in NIH 3T3 fibroblasts (Fig. 1, D and
E). In addition, RT-PCR analysis revealed expression of
OSMR and gp130 mRNA in these cells (Fig. 1G). In both the
mCFs and NIH 3T3 cells, IL-6 receptor expression was not
detected using flow cytometry or by RT-PCR (Fig. 1, C, F, and
G). RT-PCR analysis also revealed the presence of LIF recep-
tor mRNA, but not IL-11 receptor mRNA, in mCFs and NIH
3T3 cells. The CXC chemokines MIP2, KC, and LIX were
examined in supernatants collected from cultured mCFs treated
for 24 h with recombinant mouse OSM. Figure 2 shows that
mCFs treated with OSM exhibited dose-dependent increases in
the amount of KC and LIX released into the culture supernatant
(Fig. 2A). OSM did not increase MIP2 secretion. However,
TNF- induced a dose-dependent release of MIP2 (Fig. 2B),
confirming that the mCFs were capable of MIP2 secretion. KC
and LIX secretion was significantly inhibited in the presence of
an anti-mouse OSM neutralizing MAb (Fig. 2, C and D).
Secretion of CXC chemokines by mCFs in response to other
members of the IL-6 family of cytokines. To determine whether
the ability of OSM to regulate CXC chemokine induction in
mCFs is unique among members of the IL-6 family of cyto-
Fig. 3. Regulation of KC and LIX release by
the IL-6 family of cytokines in adult mCFs
and NIH 3T3 cells. mCFs (A and B) and NIH
3T3 cells (C and D) were plated in 24-well
plates and treated in serum-free media with
20 ng/ml of each member of the IL-6 family
of cytokine OSM for 24 h in quadruplicate.
Protein amounts of KC, LIX, and MIP2 re-
leased in supernatants were measured by
ELISA. Data represent means  SE of 2
independents experiments conducted in qua-
druplicate. *P  0.05, **P  0.01, and
***P  0.001 vs. control.
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kines, we stimulated mCFs and NIH 3T3 cells with a 20 ng/ml
concentration of each of the following: OSM, IL-6, LIF, IL-11,
and CT-1. In mCFs, only OSM significantly increased the
release of KC and LIX (Fig. 3, A and B). Even with an elevated
dose (100 ng/ml), IL-6, LIF, IL-11, and CT-1 failed to induce
CXC chemokine secretion (data not shown). Neither OSM
(Fig. 2A) nor other members of the IL-6 family of cytokines at
10, 20, or 100 ng/ml increased the release of MIP2 (data not
shown). In NIH 3T3 cells, OSM significantly increased the
release of KC (Fig. 3C) and LIX (Fig. 3D). However, in
contrast to mCFs, LIX release was observed in response to LIF,
IL-11, and CT-1, but to a lesser extent than in response to
OSM, confirming the biological activity of these cytokines.
Activation of JAK-STAT, MAPK, and PI3-kinase pathways
in mCFs. To determine whether OSM activates the JAK-
STAT, MAPK, and PI3-kinase pathways in mCFs, the lysates
of mCFs treated with OSM were probed after Western blot
analysis using antibodies against phosphorylated and total
STAT1, STAT3, ERK1/2, and Akt. We found that at 10 ng/ml,
OSM activated STAT1, STAT3, ERK1/2, and Akt (Fig. 4A) in
a time-dependent manner. Neither IL-6, LIF, IL-11, or CT-1
activated STAT1 or STAT3 in mCFs (Fig. 4B). Phosphoryla-
tion of the STATs was not detected at 10 min, even when IL-6,
LIF, IL-11, and CT-1 concentrations were increased to 100
ng/ml (data not shown). However, in addition to OSM, LIF and
IL-11 activated STAT3 and Akt in NIH 3T3 cells, although to
a lesser degree (Fig. 4C).
Regulation of OSM-induced CXC chemokine expression in
mCFs. OSM induction of the CC chemokine eotaxin in mouse
NIH 3T3 cells is partially dependent on the activation of the
MAPK pathway (26). To determine whether activation of the
MAPK and PI3-kinase pathways is involved in OSM-induced
CXC chemokine release, we treated mCFs with increasing
doses of PD-98059 (a pharmacological inhibitor of MEK1 of
the MAPK pathway) or LY-294002 (a specific inhibitor of
PI3-kinase) before treatment with OSM. Also, using the phar-
macological inhibitor AG 490, we tested whether JAK2 of the
JAK-STAT pathway is involved in OSM-induced chemokine
release. At 24 h, LY-294002 produced a dose-dependent de-
crease in the OSM-induced release of KC and LIX (Fig. 5, A
and B). By contrast, PD-98059 (Fig. 5, C and D) and the JAK2
inhibitor AG 490 (Fig. 5, E and F), under the same conditions,
did not decrease LIX or KC secretion significantly.
To determine whether OSM regulates the induction of the
CXC chemokines at the level of transcription, we performed a
RNase protection assay on total RNA isolated from the lysates
of mCFs treated with 10 ng/ml OSM at time intervals up to
24 h. We found that KC mRNA was not detected at time 0 but
was elevated at 30 min and 1 h after OSM stimulation (Fig.
6A). KC mRNA was not detectable beyond 2 h. Consistent
with the observed lack of MIP2 protein induction after OSM
treatment, OSM failed to increase MIP2 mRNA expression.
KC mRNA induction demonstrated dose dependence on OSM
concentration, but MIP2 mRNA expression did not (Fig. 6B).
mCFs were capable of MIP2 mRNA expression, as evidenced
by an inductive response to both TNF and LPS (data not
shown). Although LIX mRNA was present in mCFs, we were
unable to determine changes in mRNA expression (see Sup-
plemental Data).
DISCUSSION
In this study, we have demonstrated for the first time that
mCFs in culture express OSMR and that OSM, a member of
the IL-6 family of cytokines, induces CXC chemokine expres-
sion in mCFs. Previous reports documented OSMR mRNA
expression in the developing mouse heart (35) and suggested
the expression of OSMR protein in human cardiac myocytes
(41). However, no reports have been published to date regard-
ing the surface expression of OSMR on mCFs. Our results
provide direct evidence for the expression of the OSMR on the
Fig. 4. JAK-signal transducer and activator of transcription (JAK-STAT),
MAPK, and phosphatidylinositol 3-kinase (PI3-kinase)-Akt pathway activa-
tion by the IL-6 family of cytokines in mCFs and NIH 3T3 cells. mCFs and
NIH 3T3 cells were allowed to rest in serum-free media for 2 h before being
stimulated with 10 ng/ml OSM, IL-6, LIF, IL-11, cardiotrophin-1 (CT-1), or
increasing doses of OSM. For time-dependent response to OSM, total cell
lysates were collected at 10, 30, 60, and 120 min. Western blot analysis of
lysates was performed using antibodies against total and phosphorylated
forms of STAT1, STAT3, ERK1/2, and Akt. Western blot analysis shown
in A represents 2 experiments conducted to assess time-dependent activa-
tion of STAT1, STAT3, ERK1/2, and Akt by OSM, and Western blot
analyses shown in B and C represent responses of mCFs and NIH 3T3 cells
to stimulation by 10 ng/ml concentrations of IL-6 family of cytokines for
10 min.
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surface of adult mCFs (Fig. 1B) and confirm the surface
expression of gp130, the common cell membrane receptor for
the IL-6 family of cytokines (Fig. 1A). In response to OSM,
mCFs secrete the CXC chemokines KC and LIX, both of
which are potent neutrophil chemoattractants. On the basis of
inhibitor studies of the JAK-STAT, MAPK, and PI3-kinase
pathways, we have shown that OSM induction of KC and LIX
release involves PI3-kinase activation. Altogether, these data
suggest an important role for OSM as an inducer of specific
CXC chemokine release from resident cardiac fibroblasts.
Fig. 5. Role of PI3-kinase, MAPK, and JAK-STAT pathways in OSM-mediated regulation of KC and LIX release in mCFs. mCFs were plated in 24-well plates
and treated in triplicate with increasing doses of PI3-kinase inhibitor LY-294002 (LY294), MAPK pathway inhibitor PD-98059 (PD98), and JAK2 inhibitor AG
490 in serum-free media for 1 h. Next, mCFs were treated with 10 ng/ml OSM for 24 h. Protein amounts of KC and LIX released in cell culture supernatants
were measured by ELISA. Values shown for LY-294002 (A and B)-, PD-98059 (C and D)-, and AG 490 (E and F)-treated cells are means  SE of 3 independent
experiments conducted in triplicate. *P  0.05, **P  0.01, and ***P  0.001 vs. control.
Fig. 6. OSM regulation of KC and MIP2 mRNA levels in
mCFs. mCFs were stimulated with OSM in serum-free
media. Total RNA was isolated as described in MATERIALS
AND METHODS and analyzed for KC and MIP2 expression
by performing a RNase protection assay. For induction
kinetics studies, 10 ng/ml OSM was added for different
time periods (A). For dose-dependent studies, increasing
doses of OSM were used and cells were harvested after 30
min of stimulation (B). Data in graphs represent relative
band intensities of mRNA obtained using a PhosphorIm-
ager and normalized to the housekeeping gene L32.
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The presence of the OSMR, along with gp130, supports the
notion that OSM may regulate cardiac fibroblast function
directly. In response to OSM treatment, mCFs secrete the CXC
chemokines KC and LIX, two of the three known potent
neutrophil chemoattactants in the mouse (Fig. 2A). These
results are consistent with previously published findings doc-
umenting that OSM induces endothelial synthesis of GROs and
ENA-78, functional orthologs of KC and LIX, respectively
(27). Consistent with KC release, OSM induced a time (Fig.
6A)- and dose (Fig. 6B)-dependent increase in KC mRNA
transcription levels. It is well established that chemokine up-
regulation, including the CXC chemokine IL-8, can be the
result of increased transcriptional activity as well as of in-
creased posttranscriptional mRNA stability (21, 34, 39).
Whether the increased level of OSM-induced KC mRNA
transcripts is due to an increase in mRNA stability or the
induction of mRNA transcription, or both, is not known.
However, it is worth noting that basal levels of KC mRNA
were undetectable before stimulation. OSM treatment has no
effect on the MIP2 mRNA transcription level, which is con-
sistent with the lack of MIP2 secretion. Our RT-PCR experi-
ments have shown that LIX mRNA transcripts were detectable
in mCFs; however, OSM treatment did not appear to alter its
levels (Supplemental data for this article may be found at
http://ajpcell.physiology.org/cgi/content/full/00322.2005/DC1).
Selectivity in CXC chemokine induction by OSM has been
observed in other species. For example, in humans (lung
fibroblasts, synovial fibroblasts, and brain endothelial cells),
OSM does not induce the synthesis or release of IL-8 (31) or
the release of MIP2 in rat mesangial cells (19). The inability of
OSM to induce the synthesis of MIP2 in mCFs cannot be
explained by the cells’ inability to synthesize MIP2, because
mCFs synthesize and release MIP2 upon stimulation with
TNF- (Fig. 2B).
Our study has demonstrated the apparent uniqueness of
OSM among the members of the IL-6 family of cytokines in its
ability to induce CXC chemokines in mCFs (Fig. 3, A and B).
Even at high cytokine concentrations, OSM but not IL-6, LIF,
IL-11, or CT-1 increased the release of KC and LIX (data not
shown). This distinctive ability of OSM to regulate CXC
chemokine expression is similar to observations in mouse lung
fibroblasts, in which OSM but not other IL-6 family members
significantly induced the release of the CC chemokine eotaxin
(26). The inability of IL-6 to induce CXC chemokine secretion
in mCFs is consistent with the apparent lack of IL-6 receptors
in mCFs as measured using flow cytometry and RT-PCR.
Whether the inability of LIF, IL-11, or CT-1 to regulate CXC
chemokine secretion in mCFs is due to the lack of, or to
inadequate levels of, surface expression of their respective
receptors or is due to their inability to activate the necessary
pathways for CXC chemokine synthesis is not clear. Our
studies with NIH 3T3 cells also have shown that OSM alone
was able to induce secretion of KC. However, in contrast to
mCFs, LIF, IL-11, and CT-1 induced the release of LIX in NIH
3T3 cells (Fig. 3C), suggesting a differential regulation of KC
and LIX in these cells. Still, the release of LIX by NIH 3T3
cells treated with LIF, IL-11, and CT-1 was much less than that
released by NIH 3T3 cells treated with OSM.
To understand OSM regulation of CXC chemokines in
mCFs, we studied the main signaling pathways activated by
OSM (20). We have demonstrated that OSM induces rapid (10
min), marked activation of the JAK-STAT, MAPK, and PI3-
kinase-Akt pathways in mCFs (Fig. 4A). Activation of ERK by
OSM in mCFs is consistent with published data showing ERK
activation by OSM in NIH 3T3 cells (26). Activation of the
PI3-kinase pathway by OSM is also consistent with previous
data regarding the activation of PI3-kinase by OSM in Kaposi
sarcoma (33). LIF, IL-11, and CT-1 did not activate STAT1
and STAT3 in mCFs. These results support the notion that, on
the surface of primary cultured mCFs, the receptors for IL-6,
LIF, IL-11, and CT-1 are not expressed or that their expression
levels are not sufficient to activate the JAK-STAT pathway.
However, it should be noted that LIF regulates collagen syn-
thesis in mCFs (40), suggesting that the LIF receptor is ex-
pressed in mCFs. It also should be noted that CT-1 regulates
remodeling in rat and dog cardiac fibroblasts (3, 12, 13). This
finding suggests that the expression of these receptors is
species specific and/or is inducible under different culture
conditions. In contrast to the mCFs, LIF and IL-11, in addition
to OSM, activated the JAK-STAT pathway in NIH 3T3 cells,
although we could not detect IL-11 receptor mRNA in the NIH
3T3 cells. Although they were less potent than OSM, these
responses suggest that, in contrast to mCFs, the LIF and IL-11
receptors are sufficiently expressed in NIH 3T3 cells.
Although the PI3-kinase pathway has been recognized as an
important mediator of IL-6 cytokine family activity (1, 2, 5, 33,
38), its role in inflammation is not clear. Our study has
demonstrated that the PI3-kinase pathway contributes to OSM-
induced CXC chemokine release by mCFs because PI3-kinase
inhibitor LY-294002 significantly decreased the release of KC
and LIX in OSM-treated mCFs in a dose-dependent manner
(Fig. 5, A and B). The MEK1 inhibitor PD-98059 (Fig. 5, C and
D) and JAK2 blocker AG 490 (Fig. 5, E and F) did not
significantly decrease the release of KC and LIX from mCFs.
These results suggest that MEK1 and JAK2 are not involved in
OSM-mediated CXC chemokine release. However, a role for
other branches of the MAPK pathway, for JAK1, or for other
upstream signaling proteins cannot be ruled out. Our results
clearly demonstrate that the PI3-kinase pathway plays an
important role in OSM-induced chemokine release in mCFs;
however, the mechanisms involved remain to be determined.
In conclusion, we report herein for the first time that the
OSMR is expressed in adult mCFs in vitro and that OSM is
unique among the IL-6 family of cytokines in its ability to
induce CXC chemokine expression in cardiac fibroblasts. This
regulation is at least partially dependent on PI3-kinase activa-
tion. A growing body of literature supports a role for fibro-
blasts in a variety of acute and chronic inflammatory settings.
Our results suggest that cardiac fibroblasts may also contribute
to the evolution of inflammation in the heart. Specifically, in
the setting of acute myocardial infarction, OSM released in the
reperfused myocardium may trigger cardiac fibroblasts to syn-
thesize and release CXC chemokines, thereby providing a
mechanism for enhanced neutrophil recruitment and amplifi-
cation of the acute inflammatory response.
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